Dr. Reddy's is ready to buy OctoPlus shares; Tamiflu vaccine scandal rages in U.K.;

@FiercePharma: WSJ: Pfizer animal health IPO could happen next month. Story | Follow @FiercePharma

> Vanda Pharmaceuticals ($VNDA) has had its schizophrenia drug Fanaptum given a thumbs-down by the panel that makes recommendations to the European Commission. Story

> Dr. Reddy's offer to buy the shares of Netherlands-based OctoPlus begins today and runs through Feb. 8. Item

> A study casts doubt on the benefits of using a cannabis extract spray made by GW Pharmaceuticals for spasticity in patients with multiple sclerosis. Story

> Australian pharmaceutical group Mayne Pharma says it intends to raise about $19 million so it can buy the morphine-based pain-relief product Kapanol from GlaxoSmithKline ($GSK). Item

> The controversy in the U.K. over the Tamiflu vaccine continues with some members of Parliament calling for a probe into the trials of the drug, which has been stockpiled globally since 2009. Story

Medical Device News

 @FierceMedDev: InVivo Therapeutics is seeing an HDE for its biopolymer scaffolding product. Clinical trial starts in early 2013. News | Follow @FierceMedDev

@MarkHFierce: Zoll says its "temperature management solution" device treated 17 pilgrims with heat stroke on their way to Mecca. More | Follow @MarkHFierce

 @DamianFierce: Barack Obama has no interest in a delay on the 2.3% medical device tax. News | Follow @DamianFierce

> Study: Cardiac-arrest patients often endure debilitating mental fallout. Item

> Cheap Dx spots lung cancer mutation ripe for Pfizer drug. Story

Biotech News

 @FierceBiotech: Genentech readies for groundbreaking $100M trial of Alzheimer's therapy. News | Follow @FierceBiotech

@JohnCFierce: Cowen out with list of top 10 potential surprises in '13; includes early OK on asfotase, restricting CRPC drugs to metastatic patients. List | Follow @JohnCFierce

@RyanFierce: EMA committee shoots down Sanofi's cholesterol drug mipomersen. News | Follow @RyanMFierce

> Cowen lists top 10 potential surprise catalysts for 2013. Report

> Roche gains blockbuster backing for breast cancer therapy in Europe. Story

And Finally... We note the passing of the 91-year-old N. Joseph Woodland, who envisioned the process on which the modern--and now ubiquitous--bar code is based, a technology that is essential to modern drugmaking. Obituary

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.